Spyre Therapeutics (NASDAQ:SYRE) Lowered to “Sell” Rating by Wall Street Zen

Spyre Therapeutics (NASDAQ:SYRE) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also weighed in on the company. Citigroup began coverage on Spyre Therapeutics in a research report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $70.00 price target on shares of Spyre Therapeutics in a research report on Friday. Mizuho upgraded Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Wells Fargo & Company raised their target price on shares of Spyre Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $53.44.

Spyre Therapeutics Stock Performance

Shares of NASDAQ SYRE opened at $43.21 on Friday. The firm’s 50 day moving average price is $33.40 and its 200-day moving average price is $25.29. Spyre Therapeutics has a 52-week low of $10.91 and a 52-week high of $43.56. The company has a market cap of $3.35 billion, a PE ratio of -20.77 and a beta of 3.15.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). On average, analysts forecast that Spyre Therapeutics will post -4.46 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $32.80, for a total value of $492,000.00. Following the completion of the sale, the chief executive officer directly owned 657,540 shares of the company’s stock, valued at $21,567,312. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 45,000 shares of company stock worth $1,387,500. 15.43% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Spyre Therapeutics

A number of large investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its position in Spyre Therapeutics by 149.6% in the 4th quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company’s stock valued at $100,548,000 after acquiring an additional 1,839,780 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Spyre Therapeutics by 13,969.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock valued at $59,918,000 after purchasing an additional 1,816,009 shares during the period. RA Capital Management L.P. bought a new position in shares of Spyre Therapeutics in the fourth quarter worth about $53,124,000. Remedium Capital Partners LLC purchased a new position in Spyre Therapeutics in the 4th quarter worth about $47,706,000. Finally, TCG Crossover Management LLC purchased a new position in Spyre Therapeutics in the 3rd quarter worth about $18,446,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.